Key result
A single administration of rhBNP-Fc mRNA-LNP extended the half-life of rhBNP and significantly improved cardiac function and mitigated myocardial damage in a mouse model of heart failure.
Why the study?
Clinical application of rhBNP for heart failure therapy is limited by its very short half-life.
Does rhBNP-Fc mRNA-LNP improve cardiac function and reduce biomarkers in a doxorubicin-induced heart failure mouse model?
Does rhBNP-Fc mRNA-LNP improve cardiac function and reduce biomarkers in a doxorubicin-induced heart failure mouse model?
rhBNP-Fc mRNA-LNP extends the half-life of rhBNP and effectively improves cardiac function in a preclinical model of doxorubicin-induced heart failure, highlighting its potential as a long-acting protein replacement therapy.
Answers are grounded in this paper and cite their sources.
Supports preclinical development of long-acting rhBNP in heart failure; leaves open translation to human trials.
PURPOSE: Recombinant human B-type natriuretic peptide (rhBNP) has been extensively proven to be an effective mean of heart failure (HF) therapy, but its clinical application is limited by its very short half-life. This study aims to combine in vitro transcribed mRNA (IVT mRNA) and fusion protein technology to develop a rhBNP-Fc mRNA drug with long half-life, high efficiency and few side effects to treat HF. METHODS: The rhBNP-Fc fusion mRNA with IgG4-Fc sequence was produced by IVT technology. rhBNP-Fc mRNA was transfected into HEK293T cells to examine the expression in vitro. rhBNP-Fc mRNA encapsulated in LNP was injected into normal mice to detect the translation efficiency, half-life and negative effects in vivo. Finally, it was injected into doxorubicin-induced HF mice to screen the cardiac protective effect. RESULTS: The rhBNP-Fc fusion mRNA extended the half-life of rhBNP, showing sustained expression in cell line for at least one day. rhBNP-Fc mRNA translation showed dose-dependent levels, and was still detectable 5 d after injection in vivo. In the HF mouse model, a single administration of rhBNP-Fc mRNA-LNP improved cardiac function, including improving heart ejection and reducing HF biomarkers expression. Additionally, rhBNP-Fc mRNA-LNP treatment mitigated myocardial damage, normalized cardiomyocyte structure, and reduced the levels of pro-inflammatory cytokines. CONCLUSION: The rhBNP-Fc mRNA has the potential to serve as an alternative to traditional protein therapies, thereby reducing clinical dosages, injection frequencies, and treatment costs. Our findings offer new insights into the development and application of mRNA drugs, emphasizing their therapeutic potential in long-acting drugs.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied Heart failure (doxorubicin-induced) (n=24). rhBNP-Fc mRNA-LNP vs. Saline and rhBNP protein was evaluated on Cardiac function (ejection fraction and fractional shortening) and rhBNP half-life. A single administration of rhBNP-Fc mRNA-LNP extended the half-life of rhBNP and significantly improved cardiac function and mitigated myocardial damage in a mouse model of heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: